Sociedad Americana de Hirudoterapia

Heparin Induced Thrombocytopenia In The Setting Of Urgent Cardiac Surgery: Can Bivalirudin Be A Safe Option? - A Case Report

Case report published in Portuguese Journal of Cardiac Thoracic and Vascular Surgery (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportDesarrollo de fármacosAlves B et al. · Portuguese Journal of Cardiac Thoracic and Vascular Surgery, 2025

Abstract

Unfractionated heparin is the main anticoagulant employed in the context of cardiovascular surgery. When a patient with heparin induced thrombocytopenia (HIT) is proposed for cardiac surgery, the anticoagulation management is challenging. Bivalirudin is an alternative to heparin in the perioperative setting. We present a rare case of a patient with HIT and cardiogenic shock that required bivalirudin use in the perioperative period of an urgent reoperation of recurrent mitral valve dysfunction. Although infrequent, the use of bivalirudin can be safe in high risk patients if adequate measures follow institutional protocols, as reported in this case.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleCase Reports
Indexed MeSH termsHumansAnticoagulantsAntithrombinsHeart Valve Prosthesis ImplantationHeparinHirudinsMitral Valve InsufficiencyPeptide FragmentsRecombinant ProteinsReoperationShock, CardiogenicThrombocytopenia

Resumen

Heparin Induced Thrombocytopenia In The Setting Of Urgent Cardiac Surgery: Can Bivalirudin Be A Safe Option? - A Case Report.

Por qué esto importa para la hirudoterapia

This case report describes a patient with heparin-induced thrombocytopenia (HIT) and cardiogenic shock who received bivalirudin during the perioperative period of an urgent reoperation for recurrent mitral valve dysfunction, with a reportedly safe outcome under institutional protocols. The abstract discusses bivalirudin as an alternative to heparin in the perioperative setting but provides no detail on its mechanism beyond clinical use. For ASH, no defensible leech or hirudotherapy connection exists from the abstract: it does not mention leeches, hirudin, or leech-derived therapy. Honest caveat: this is a single case report involving no leeches or leech therapy, and it does not establish efficacy or safety beyond the described individual.

Citación

Heparin Induced Thrombocytopenia In The Setting Of Urgent Cardiac Surgery: Can Bivalirudin Be A Safe Option? - A Case Report

Alves B et al. · Portuguese Journal of Cardiac Thoracic and Vascular Surgery, 2025

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsHirudinAnticoagulation CompoundsBivalirudinHemostasisCardiovascularCardiologyOtolaryngology

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.